AdamCrystalMD

Chief Medical Officer, C4 Therapeutics.

Dr. Crystal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
C4 Therapeutics, Inc
490 Arsenal Way, Suite 100
East Watertown, MA 02472

Medical oncologist (MD-PhD), board certified; Industry experience in early phase oncology drug development including small molecules, IO and CAR-T; Translational research: acquired resistance to targeted therapy in lung cancer.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2013
Massachusetts General HospitalInternship, Internal Medicine, 2006 - 2007
Perelman School of Medicine at the University of PennsylvaniaClass of 2006

PubMed

215 citations
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas
Jeffrey R. Infante, P. A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh
Clinical Cancer Research. 2016-12-01
656 citations
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald, Maria Gomez-Caraballo, Faria M. Siddiqui
Nature Medicine. 2016-03-01
625 citations
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Luc Friboulet, Nanxin Li, Ryohei Katayama, Christian C. Lee, Justin F. Gainor
Cancer Discovery. 2014-03-27

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingApril 18th, 2023
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsMarch 27th, 2023
AACR: C4's Multiple Myeloma Data Prompts Dosing Switch, Giving Patients a Longer Treatment ReprieveApril 8th, 2022
Join now to see all